Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. BPMC.NASDAQ

Blueprint Medicines Corp (BPMC NASDAQ) stock market data APIs

$115.9 3.71(3.3%) as of July 26, 2024
Price chart is built with Anychart

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Blueprint Medicines Corp Financial Data Overview

112.19
115.9
-
116.51
112.02
43.89-121.9
7 110 M
62 617 K
282 M
1.4
0.63
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'BPMC',
Type: 'Common Stock',
Name: 'Blueprint Medicines Corp',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG001MC8YF7',
ISIN: NULL,
CUSIP: NULL,
CIK: '1597264',
EmployerIdNumber: '26-3632015',
FiscalYearEnd: 'December',
IPODate: '2015-04-30',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'Domestic',
IsDelisted: false,
}

Blueprint Medicines Corp Fundamental Data is available in our Financial Data APIs

  • Net Revenue 282 M
  • EBITDA -428 102 016
  • Earnings Per Share -4.82
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Blueprint Medicines Corp Earnings via APIs

  • Latest Release 2024-05-02
  • EPS/Forecast -1.66

Get Blueprint Medicines Corp End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Blueprint Medicines Corp latest news via APIs

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?

The market expects Blueprint Medicines (BPMC) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus o...

Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024

CAMBRIDGE, Mass., July 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August ...
Do you have any questions?
support@eodhistoricaldata.com